TABLE 2.
Vaccination properties and side effects of the patients
| N = 35 | ||
|---|---|---|
| BNT162b2 | CoronaVac | |
| Patients ever vaccinated with BNT162b2 or CoronaVac, n | 20 | 18 |
| Vaccine distribution of patients, n | ||
| 3 doses of CoronaVac | 7 | |
| 2 doses of CoronaVac | 7 | |
| 1 dose of CoronaVac | 1 | |
| 3 doses of BNT162b2 | 1 | |
| 2 doses of BNT162b2 | 16 | |
| 3 doses of CoronaVac + single dose of BNT162b2 | 3 | |
| Patients vaccinated with BNT162b2 or CoronaVac alone, n (%) | 17 (48.6) | 15 (42.9) |
| Patients with an adverse effect after a dose of BNT162b2 or CoronaVac, n (%) | 9/20 (45.0) | 7/18 (38.9) |
| Adverse reactions, n (%) a | ||
| Fever | 3 (15) | 0 (0) |
| Malaise | 4 (20) | 4 (22.2) |
| Local pain/arm pain | 1 (5) | 3 (16.6) |
| Myalgia | 6 (30) | 6 (33.3) |
| Patients with an adverse effect after 1st dose of BNT162b2 or CoronaVac, n (%) | 7 (35) | 2 (11.1) |
| Adverse reactions, n (%) a | ||
| Fever | 3 (15) | 0 |
| Malaise | 4 (20) | 2 (11.1) |
| Local pain/arm pain | 2 (10) | 0 |
| Myalgia | 3 (15) | 1 (5.5) |
| Patients with an adverse effect after 2nd dose of BNT162b2 or CoronaVac, n (%) | 6/20 (30) | 5/18 (27.8) |
| Adverse reactions, n (%) a | ||
| Fever | 3 (15) | 0 |
| Malaise | 1 (5) | 3 (16.6) |
| Local pain/arm pain | 1 (5) | 0 |
| Myalgia | 5 (25) | 3 (16.6) |
| Patients with an adverse effect after a booster dose with BNT162b2 or CoronaVac, n (%) b | 1/4 (25) | 4/7 (57.1) |
| Adverse reactions, n (%) a | ||
| Fever | 0 | 0 |
| Malaise | 1 (25) | 3 (42.8) |
| Local pain/arm pain | 0 | 2 (28.5) |
| Myalgia | 1 (25) | 3 (42.8) |
a
Out of patients with adverse events.
b
Out of 11 patients who had a booster dose, 7 with CoronaVac, 4 with BNT162b2.